Aegis still positive on CytRx, sees big upside


Aegis is out with some upbeat commentary on CytRx (CYTR +3%), noting that despite the appearance of "a higher incidence of adverse events on aldoxorubicin ... all grade 3 or 4 thrombocytopenia, mucositis, or nausea / vomiting events are manageable and resolve."

As for the PFS outlook for aldoxorubicin, analyst Ram Selvaraju says "numbers of patients completing either four or six cycles both favor" the drug which, when "coupled with the 22% versus 0% PR rate favoring aldox may be predictive of positive PFS data."

Price target is $7 (so, upside of 200%+ from Friday's close).

For more on the data Selvaraju is referencing, see here.

From other sites
Comments (1)
  • mitrado
    , contributor
    Comments (2033) | Send Message
     
    Hmmm... does this means it will trade around $0.7 in a near future? (I completely distrust these PTs.)

     

    Just to remind some price targets (set not too long ago):

     

    $AMRN PT: > $30
    Reality: $1.7

     

    $DNDN PT: > $18
    Reality: $2.76

     

    $SRPT PT: > $50
    Reality: $15.87

     

    $SPPI PT: > $30
    Reality: $9.47

     

    Tell me again, why should I trust Price Targets for Bio-Tech companies?
    25 Nov 2013, 10:00 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs